ADC Therapeutics SA Form 6-K Summary
Business Context and Reporting Period
ADC Therapeutics SA filed a Form 6-K dated May 5, 2023, covering the month of May 2023. The filing concerns corporate governance and shareholder meeting matters, not operating or financial results.
Annual General Meeting
- The annual general meeting is expected to be held on June 14, 2023, at 4:00 a.m. EDT / 10:00 a.m. CEST.
- The meeting is scheduled at the Company’s headquarters in Epalinges, Switzerland.
- The Company provided shareholders with an invitation and related meeting materials.
Financial Metrics and Material Changes
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics. It does not describe material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
No management outlook, risk update, contingency, or unusual financial item is disclosed in the filing text.
Investor Verification Items
- Review the annual general meeting invitation for the meeting agenda, proposed resolutions, and voting procedures.
- Review the shareholder meeting notice and proxy cards for record-date requirements and submission deadlines.
- Confirm any resolutions or corporate actions approved at the June 14, 2023 annual general meeting.
Exhibits
- Exhibit 99.1: Invitation to the Annual General Meeting
- Exhibit 99.2: ADC Therapeutics SA Shareholder Meeting Notice
- Exhibit 99.3: Annual General Meeting Proxy Card for Record Holders
- Exhibit 99.4: Annual General Meeting Proxy Card for Brokers